Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as a delayed‑release oral tablet for oral use. It treats acid‑related disorders such as gastro‑oesophageal reflux disease, erosive oesophagitis and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nolpaza (pantoprazole) is a proton pump inhibitor used to manage conditions driven by excess gastric acid.

- Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and regurgitation. - Erosive oesophagitis: promotes healing of acid‑induced esophageal lesions. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid associated with gastrin‑producing tumors. - Prevention of NSAID‑induced gastric ulcers: lowers ulcer risk in patients requiring long‑term NSAID therapy.

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, often transient. - Nausea: feeling of stomach upset. - Abdominal pain: discomfort in the upper abdomen. - Flatulence: increased gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhea, abdominal cramping. - Low magnesium levels: muscle cramps, irregular heartbeat. - Liver enzyme elevation: abnormal liver function tests. - Bone fracture risk: especially with long‑term use. - Acute interstitial nephritis: kidney inflammation presenting with fever and urinary changes.

Before initiating Nolpaza, consider the following safety measures.

- Assess renal function: dose adjustment may be needed in severe impairment. - Review hepatic status: monitor liver enzymes in patients with liver disease. - Evaluate for infections: use cautiously in patients with a history of C. difficile. - Monitor electrolytes: especially magnesium during prolonged therapy. - Pregnancy and lactation: discuss risks with a healthcare provider as safety data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption; avoid concurrent use. - Atazanavir: markedly decreased antiviral exposure; contraindicated.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: slight increase in serum levels; check renal function. - Methotrexate (high dose): reduced clearance; monitor for toxicity. - Clopidogrel: diminished antiplatelet effect; consider alternative therapy. - Iron supplements: decreased iron absorption; separate administration by at least 2 hours.